

REMARKS

The amendment to page 2 of the Specification corrects an inadvertent error concerning the number of Derwent Publication and the chemical compound mentioned in the publication.

No new matter is being added.

The Second Information Disclosure Statement being filed herewith contains a copy of Derwent Publication No. XP002241615. This Second Information Disclosure Statement is being filed prior to the first Office Action so no fee is due.

Also enclosed are two signed original Declarations. Applicant authorizes the Commissioner to charge all fees due for late filing of the Declarations to Deposit Account 19-0134.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7922


David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: July 27, 2005